1月26日,国家药品监督管理局(NMPA)正式批准维升药业(2561.HK)的核心产品——隆培生长激素注射液上市,该产品用于治疗儿童生长激素缺乏症(PGHD)。这款每周注射一次的长效生长激素,是国内首个且唯一经三期临床试验证实,其疗效优于日制剂的产品。 根据公开信息,2021年,隆培生长激素在美获批上市,用于治疗体重至少11.5公斤(25.4 磅)且因内源性生长激素 (GH) 分泌不足而导致生长...
Source Link1月26日,国家药品监督管理局(NMPA)正式批准维升药业(2561.HK)的核心产品——隆培生长激素注射液上市,该产品用于治疗儿童生长激素缺乏症(PGHD)。这款每周注射一次的长效生长激素,是国内首个且唯一经三期临床试验证实,其疗效优于日制剂的产品。 根据公开信息,2021年,隆培生长激素在美获批上市,用于治疗体重至少11.5公斤(25.4 磅)且因内源性生长激素 (GH) 分泌不足而导致生长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.